Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Mayne Pharma Group's share price for the quarter that ended in Dec. 2025 was A$3.11. Mayne Pharma Group's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 81.2 Mil. Therefore, Mayne Pharma Group's market cap for the quarter that ended in Dec. 2025 was A$252.7 Mil.
Mayne Pharma Group's quarterly market cap
increased
from Dec. 2024 (A$403.8 Mil) to Jun. 2025 (A$406.2 Mil) but then
declined
from Jun. 2025 (A$406.2 Mil) to Dec. 2025 (A$252.7 Mil).
Mayne Pharma Group's annual market cap
increased
from Jun. 2023 (A$367.1 Mil) to Jun. 2024 (A$382.7 Mil) and
increased
from Jun. 2024 (A$382.7 Mil) to Jun. 2025 (A$406.2 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mayne Pharma Group's Enterprise Value for Today is A$181.6 Mil.
Mayne Pharma Group (ASX:MYX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Mayne Pharma Group Market Cap Related Terms
Mayne Pharma Group Market Cap Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Mayne Pharma Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group Market Cap vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Mayne Pharma Group's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group (ASX:MYX) has a Market Cap of A$208.8 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #62 out of 122 companies in the Medical Distribution industry, placing it in the top 50.8%.
Is Mayne Pharma Group's Market Cap too high?
Mayne Pharma Group's current Market Cap is A$208.8 Mil. Based on the distribution chart, Mayne Pharma Group ranks #62 out of 122 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Mayne Pharma Group has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Market Cap compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #62 out of 122 companies for Market Cap. This places Mayne Pharma Group in the lower half of its industry. The industry median Market Cap is 137.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Distribution company?
The median Market Cap among Medical Distribution companies is 137.62, based on 122 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Market Cap is 137.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Market Cap is A$208.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (ASX:MYX) is currently considered Possible Value Trap. The stock's GF Value™ is A$5.31, compared to a current price of A$2.57 — trading 51.6% below its estimated fair value. The current Market Cap is A$208.8 Mil. Mayne Pharma Group's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Mayne Pharma Group (ASX:MYX), the current Market Cap is A$208.8 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (ASX:MYX) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of A$2.57 is trading 51.6% below its estimated GF Value™ of A$5.31.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for ASX:MYX:
Market Cap: A$208.8 Mil
GF Value™: A$5.31 vs. price of A$2.57 (51.6% below fair value)
No single metric tells the full story. See the ASX:MYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
51GF Score
Get the complete analysis for ASX:MYX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MYX has been successfully added to your 
